浙江九洲药业股份有限公司 董事会议事规则 浙江九洲药业股份有限公司 董事会议事规则 （2025 年 10 月修订） 第一章 总 则 第一条 为了进一步规范浙江九洲药业股份有限公司（以下简称"公司"）董 事会运作程序，确保董事会依法运作，提高工作效率和进行科学决策，根据《中 华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以 下简称"《证券法》"）、《上市公司股东会规则》《上市公司治理准则》《上海证券 交易所股票上市规则》和《浙江九洲药业股份有限公司章程》（以下简称 "公司 章程"）制定本规则。 第二条 董事会是公司经营管理的决策机构，维护公司和全体股东的利益， 在公司章程和股东会的授权范围内，负责公司发展目标和重大经营活动的决策， 对股东会负责。 第二章 董事会职权 第三条 董事会依法行使下列职权： （一）召集股东会，并向股东会报告工作； （二）执行股东会的决议； （三）决定公司的经营计划和投资方案； （四）制订公司的利润分配方案和弥补亏损方案； （五）制订公司增加或者减少注册资本、发行债券或其他证券及上市方案； （六）拟订公司重大收购、收购本公司股票或者合并、分立、解散及变更公 司 ...

浙江九洲药业股份有限公司 独立董事工作制度 （2025 年 10 月修订） 第一章 总则 第一条 为进一步完善浙江九洲药业股份有限公司（以下简称"公司"）治理 结构，规范独立董事行为，充分发挥独立董事在公司治理中的作用，根据《上市 公司独立董事管理办法》《上海证券交易所股票上市规则》《上海证券交易所上市 公司自律监管指引第 1 号——规范运作》等有关法律、法规和《公司章程》的规 定，制定本制度。 第二条 独立董事是指不在上市公司担任除董事外的其他职务，并与其所受 聘的上市公司及其主要股东、实际控制人不存在直接或者间接利害关系，或者其 他可能影响其进行独立客观判断关系的董事。 独立董事应当独立履行职责，不受公司及其主要股东、实际控制人等单位或 者个人的影响。 第三条 独立董事对公司及全体股东负有忠实与勤勉义务，应当按照法律、 行政法规、中国证券监督管理委员会规定、上海证券交易所业务规则和公司章程 的规定，认真履行职责，在董事会中发挥参与决策、监督制衡、专业咨询作用， 维护公司整体利益，保护中小股东合法权益。 第四条 公司独立董事占董事会成员的比例不得低于三分之一，且至少包括 一名会计专业人士。 公司应当在董事会 ...

浙江九洲药业股份有限公司 募集资金管理制度 （2025年10月修订） 第一章 总 则 第一条 为规范浙江九洲药业股份有限公司（以下简称公司）募集资金的使 用与管理，根据中国证监会《上市公司募集资金监管规则》（证监会公告〔2025〕 10号）《上海证券交易所上市公司自律监管指引第1号--规范运作》（上证发〔2025〕 68号）等有关规定，结合公司实际情况，制定本制度。 第二条 本制度所称募集资金是指公司通过发行股票或者其他具有股权性 质的证券，向投资者募集并用于特定用途的资金，但不包括公司为实施股权激励 计划募集的资金。 浙江九洲药业股份有限公司 募集资金管理制度 第二章 募集资金的存储 本制度所称超募资金是指实际募集资金净额超过计划募集资金金额的部分。 第三条 募集资金应当专款专用。公司使用募集资金应当符合国家产业政策 和相关法律法规，践行可持续发展理念，履行社会责任，原则上应当用于主营业 务，有利于增强公司竞争能力和创新能力。 《监管规则适用指引——上市类第1号》对发行股份、可转换公司债券购买 资产并募集配套资金用途另有规定的，从其规定。 第四条 本制度是募集资金内部控制制度，公司应当按照本制度建立并完善 ...

浙江九洲药业股份有限公司 内幕信息知情人登记管理制度 浙江九洲药业股份有限公司 内幕信息知情人登记管理制度 （2025 年 10 月修订） 第一章 总则 第一条 为了加强浙江九洲药业股份有限公司（以下简称"公司"）的内幕信 息管理，进一步做好内幕信息保密工作，有效防范内幕交易等证券违法违规行为， 根据《证券法》、《上市公司监管指引第 5 号——上市公司内幕信息知情人登记管 理制度》、《上海证券交易所上市公司自律监管指引第 2 号——信息披露事务管 理》等法律、行政法规、规范性文件和《浙江九洲药业股份有限公司章程》（以 下简称"公司章程"）、《浙江九洲药业股份有限公司信息披露管理制度》的规定， 制定本制度。 第二条 本制度所称内幕信息知情人，是指《证券法》第五十一条规定的有 关人员，包括但不限于： （一）公司及公司的董事、高级管理人员； （二）持有公司百分之五以上股份的股东及其董事、监事、高级管理人员， 公司的实际控制人及其董事、监事、高级管理人员； （三）公司控股或者实际控制的公司及其董事、监事、高级管理人员； （四）由于所任公司职务或者因与公司业务往来可以获取公司有关内幕信息 的人员； （五）公司收购人或者 ...

Core Insights - Jiuzhou Pharmaceutical reported a third-quarter revenue of 1.29 billion yuan, representing a year-on-year growth of 7.37% [1] - The net profit for the third quarter was 222 million yuan, showing a year-on-year increase of 42.30% [1] - For the first three quarters, the total revenue reached 4.16 billion yuan, with a year-on-year growth of 4.92% [1] - The net profit for the first three quarters was 748 million yuan, reflecting a year-on-year increase of 18.51% [1]

Group 1 - The core point of the news is that Jiuzhou Pharmaceutical experienced a stock price increase of 5.01%, reaching 20.53 CNY per share, with a trading volume of 673 million CNY and a turnover rate of 3.79%, resulting in a total market capitalization of 18.26 billion CNY [1] - Jiuzhou Pharmaceutical, established on July 13, 1998, and listed on October 10, 2014, is primarily engaged in the research, production, and sales of chemical raw materials and pharmaceutical intermediates. The revenue composition includes 79.81% from new drug custom development and manufacturing services (CDMO), 18.22% from specialty raw materials and intermediates, and 1.96% from other sources [1] Group 2 - From the perspective of major fund holdings, Guolian Fund has one fund heavily invested in Jiuzhou Pharmaceutical. The Guolian Smart Selection Pioneer Stock A (020748) held 40,200 shares in the second quarter, accounting for 0.39% of the fund's net value, making it the third-largest holding. The estimated floating profit today is approximately 39,400 CNY [2] - The Guolian Smart Selection Pioneer Stock A (020748) has a year-to-date return of 33.41%, ranking 1275 out of 4220 in its category, and a one-year return of 42.87%, ranking 892 out of 3857. Since its inception, the fund has achieved a return of 64.42% [2]

Core Insights - The A-share market has seen a significant rally in innovative drug concept stocks, with notable increases in share prices for several companies [1] Group 1: Stock Performance - Guangxi Shengtang (广生堂) experienced a rise of approximately 18% [2] - Shutaishen (舒泰神) increased by over 12% [2] - Jimin Health (济民健康) and Anglikang (昂利康) both hit the 10% daily limit up [2] - Huahai Pharmaceutical (华海药业) rose by over 9% [2] - Frontier Biologics (前沿生物) increased by over 8% [2] - Hanyu Pharmaceutical (翰宇药业) saw a rise of over 7% [2] - Saily Medical (塞力医疗) and Jiuzhou Pharmaceutical (九洲药业) both increased by over 6% [2] Group 2: Market Capitalization and Year-to-Date Performance - Guangxi Shengtang has a market capitalization of 19.2 billion with a year-to-date increase of 269.02% [2] - Shutaishen has a market capitalization of 17.3 billion with a year-to-date increase of 389.07% [2] - Jimin Health has a market capitalization of 5.76 billion with a year-to-date increase of 61.56% [2] - Anglikang has a market capitalization of 8.31 billion with a year-to-date increase of 213.50% [2] - Huahai Pharmaceutical has a market capitalization of 31.4 billion with a year-to-date increase of 18.92% [2] - Frontier Biologics has a market capitalization of 5.544 billion with a year-to-date increase of 51.64% [2] - Hanyu Pharmaceutical has a market capitalization of 19.2 billion with a year-to-date increase of 68.35% [2] - Saily Medical has a market capitalization of 5.628 billion with a year-to-date increase of 270.91% [2] - Jiuzhou Pharmaceutical has a market capitalization of 18.5 billion with a year-to-date increase of 56.50% [2]

Group 1 - The core viewpoint of the news is that Jiuzhou Pharmaceutical experienced a stock price increase of 5.28%, reaching 20.32 CNY per share, with a total market capitalization of 18.074 billion CNY [1] - Jiuzhou Pharmaceutical, established on July 13, 1998, and listed on October 10, 2014, specializes in the research, production, and sales of chemical raw materials and pharmaceutical intermediates [1] - The company's main business revenue composition includes 79.81% from new drug custom development and production services (CDMO), 18.22% from specialty raw materials and intermediates, and 1.96% from other sources [1] Group 2 - New沃 Fund has a significant holding in Jiuzhou Pharmaceutical, with the New沃 Tongying Flexible Allocation Mixed Fund (002564) holding 15,900 shares, accounting for 3.56% of the fund's net value, ranking as the tenth largest holding [2] - The New沃 Tongying Flexible Allocation Mixed Fund was established on September 22, 2016, with a latest scale of 6.8023 million CNY, and has achieved a year-to-date return of 9.96% [2] - The fund's performance over the past year shows a return of 12.66%, ranking 5,474 out of 8,015 in its category, and a cumulative return of 92.14% since inception [2]

Core Viewpoint - Jiuzhou Pharmaceutical experienced a stock price increase of 5.28%, reaching 20.32 CNY per share, with a trading volume of 228 million CNY and a total market capitalization of 18.074 billion CNY as of October 14 [1] Company Overview - Zhejiang Jiuzhou Pharmaceutical Co., Ltd. was established on July 13, 1998, and went public on October 10, 2014. The company is located at No. 99, Waisha Road, Jiaojiang District, Taizhou City, Zhejiang Province. Its main business involves the research, development, production, and sales of chemical raw materials and pharmaceutical intermediates [1] - The revenue composition of Jiuzhou Pharmaceutical includes 79.81% from new drug custom development and manufacturing services (CDMO), 18.22% from specialty raw materials and intermediates, and 1.96% from other sources [1] Shareholder Information - Among the top ten circulating shareholders of Jiuzhou Pharmaceutical, a fund under Huabao Fund holds a significant position. The Huabao CSI Medical ETF (512170) increased its holdings by 467,700 shares in the second quarter, bringing its total to 17.7854 million shares, which accounts for 2% of the circulating shares. The estimated floating profit from this investment is approximately 18.1411 million CNY [2] - The Huabao CSI Medical ETF (512170) was established on May 20, 2019, with a current scale of 26.147 billion CNY. Year-to-date returns are 15.61%, ranking 3206 out of 4220 in its category; the one-year return is 10.99%, ranking 3266 out of 3857; and since inception, the return is 13.29% [2]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" and the rating has been maintained [1] Core Insights - The pharmaceutical and biotechnology industry index experienced a decline of 2.72%, ranking 23rd among 31 primary industries, underperforming the CSI 300 index which declined by 2.62% [4][16] - The industry valuation as of September 30, 2025, is a PE (TTM overall method, excluding negative values) of 31.23x, down from 31.79x in the previous period, indicating a downward trend and below the average [21] - The top three sub-industries in terms of PE (TTM overall method, excluding negative values) are vaccines (55.74x), medical devices (41.29x), and hospitals (39.51x), with the median at 33.19x, while pharmaceutical circulation has the lowest valuation at 14.34x [21] Industry Review - The report highlights that during the reporting period, 51 listed companies in the pharmaceutical and biotechnology sector had a net reduction in shareholders amounting to 2.435 billion yuan, with 14 companies increasing their holdings by 681 million yuan and 37 companies reducing their holdings by 3.116 billion yuan [4] - The report emphasizes the importance of upcoming clinical data and the strong fundamentals of companies ahead of the ESMO 2025 conference, which is expected to showcase significant clinical research results from various domestic pharmaceutical companies [7][8] Important Industry News - AstraZeneca plans to list on the New York Stock Exchange [6] - The report mentions the approval of a new oral SERD drug by Eli Lilly, marking it as the second such drug approved globally [8][45] - The approval of the first domestic quadrivalent HPV vaccine in China is expected to expand the coverage population and potentially be priced lower than imported versions [8][50][52]